Telix Pharmaceuticals (TLX) said Wednesday it dosed the initial patient in a Phase 3 clinical trial evaluating its radiopharmaceutical therapy for recurrent glioblastoma, a type of brain cancer.

The global study will compare the safety and effectiveness of the experimental treatment combined with standard chemotherapy against chemotherapy alone, the company said.

The medication is designed to cross the blood-brain barrier to deliver targeted radiation directly to tumors, following earlier studies that demonstrated a median overall survival of approximately 13 months after treatment began, Telix said.

The trial has won regulatory clearance in several countries, including Australia and Belgium, and will use a proprietary imaging agent to select participants and monitor tumor responses, it added.

Shares of the company were down 2% in Wednesday premarket activity.